Register
Journal Updates
eMediNexus Coverage from: 
US FDA permits marketing of AI-based device to screen for diabetic retinopathy
eMediNexus,  12 April 2018
remove_red_eye 841 Views
#Business And Medicine #Diabetes and Endocrinology #Ophthalmology #Pharmacist

0 Read Comments                

The US Food and Drug Administration has permitted marketing of the first medical device ‘IDx-DR’ to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. If the images are of sufficient quality, the software provides the doctor with one of two results: (1) “more than mild diabetic retinopathy detected: refer to an eye care professional” or (2) “negative for more than mild diabetic retinopathy; rescreen in 12 months.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now